---
document_datetime: 2023-09-21 18:19:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/januvia-epar-procedural-steps-taken-authorisation_en.pdf
document_name: januvia-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.381068
conversion_datetime: 2025-12-31 05:16:30.705353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd. submitted on 6 March 2006 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Januvia,  through  the  centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 13 October 2005

The legal basis for this application refers to:

A - Centralised / Article 8(3) / New active substance.

The application submitted is a complete dossier: composed of administrative information, complete quality  data,  non-clinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or bibliographic literature substituting/supporting certain tests or studies.

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 22 January 2004 and on 24 June 2004. The Scientific Advice pertained to preclinical and clinical aspects of the dossier.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Frits Lekkerkerker

Co-Rapporteur:

Harald Enzmann

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 6 March 2006.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  20  June 2006.  The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 16 June 2006.
- The procedure started on 29 March 2006.
- During  the  meeting  on  24-27  July  2006,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 27 July 2006.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 7 September 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 20 October 2006.
- During the CHMP meeting on 13-16 November 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 12 January 2007.
- During the meeting on 22-24 January 2007, the CHMP, in light of the overall data submitted and  the  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a  Marketing Authorisation to Januvia on 24 January 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 January 2007.